



PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Oncology – BRAF and MEK Inhibitors Preferred Specialty Management Policy

BRAF/MEK Inhibitor Pairing	Mechanism of Action	Manufacturer
<ul style="list-style-type: none"> • Braftovi™ (encorafenib capsules) • Mektovi® (binimetinib tablets) 	BRAF Inhibitor	Array BioPharma
	MEK Inhibitor	
<ul style="list-style-type: none"> • Tafinlar® (dabrafenib capsules) • Mekinist® (trametinib tablets) 	BRAF Inhibitor	Novartis
	MEK Inhibitor	
<ul style="list-style-type: none"> • Zelboraf® (vemurafenib tablets) • Cotellic® (cobimetinib tablets) 	BRAF Inhibitor	Genentech/Roche
	MEK Inhibitor	

REVIEW DATE: 08/21/2024

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Cigna National Formulary Coverage:

OVERVIEW

All three of the BRAF/MEK inhibitor combinations are FDA-approved for the treatment of melanoma with *BRAF V600* mutation: Braftovi + Mektovi, Tafinlar + Mekinist, and Zelboraf + Cotellic.¹⁻⁶ In addition, these agents also have other FDA-

approved indications. Braftovi + Mektovi and Tafinlar + Mekinist combinations have FDA-approval for use in the treatment of metastatic non-small cell lung cancer (NSCLC) with a *BRAF V600E* mutation in adults, as detected by an FDA-approved test.

GUIDELINES

Metastatic or Unresectable Melanoma

The National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma (version 2.2024 – April 3, 2024) recommend BRAF/MEK inhibitor combinations for treatment of metastatic or unresectable melanoma with a *BRAF V600*-activating mutation under “other Non-Preferred Product regimens” (category 1 for all combinations) for first-line therapy.⁷ All three combinations are listed under “preferred regimens” (all category 2A) for second-line or subsequent therapy. While combination BRAF/MEK inhibition is preferred, if a combination is contraindicated, monotherapy with a BRAF inhibitor is a Non-Preferred Product option.

Metastatic Non-Small Cell Lung Cancer

Guidelines (version 7.2024 – June 26, 2024) recommend Braftovi + Mektovi and Tafinlar + Mekinist combinations for first-line “Preferred” regimens and subsequent therapies (both category 2A) for *BRAF V600E* mutation-positive disease.⁸

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of a Preferred Product prior to a Non-Preferred Product. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria and to try one of the Preferred Products prior to the approval of a Non-Preferred Product. Requests for the Non-Preferred Product will be reviewed using the exception criteria (below). If the patient meets the standard *Prior Authorization Policy* criteria for the Non-Preferred Product, but has not tried one of the Preferred Products, a review will be offered for the Preferred Products using the respective standard *Prior Authorization Policy* criteria. All approvals are provided for the duration noted below.

Melanoma:

BRAF Inhibitor Preferred Products: Zelboraf, Tafinlar

BRAF Inhibitor Non-Preferred Product: Braftovi

MEK Inhibitor Preferred Products: Cotellic, Mekinist

MEK Inhibitor Non-Preferred Product: Mektovi

Non-Small Cell Lung Cancer:

BRAF Inhibitor Preferred Product: Tafinlar

BRAF Inhibitor Non-Preferred Product: Braftovi

MEK Inhibitor Preferred Product: Mekinist

MEK Inhibitor Non-Preferred Product: Mektovi

Oncology – BRAF and MEK Inhibitors non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.

NON-PREFERRED PRODUCT EXCEPTION CRITERIA

Non-Preferred Product	Exception Criteria
Braftovi	<p>1. Melanoma, BRAF V600 Mutation-Positive Disease: Approve for 1 year if the patient meets ONE of the following (A or B):</p> <p>A) Patient meets BOTH of the following (i and ii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Oncology – Braftovi Prior Authorization (PA) Policy</i> criteria; AND ii. Patient meets ONE of the following (a or b): <ul style="list-style-type: none"> a) Patient has tried one of Zelboraf or Tafinlar; OR b) Patient is currently receiving Braftovi; OR <p>B) If the patient has met the standard <i>Oncology – Braftovi PA Policy</i> criteria, but has not met the exception criteria above (Aii), offer to review for one of the Preferred Products using either the standard <i>Oncology – Zelboraf PA Policy</i> criteria or the <i>Oncology – Tafinlar PA Policy</i> criteria.</p> <p>2. Non-Small Cell Lung Cancer, BRAF V600E Mutation-Positive Disease: Approve for 1 year if the patient meets ONE of the following (A or B):</p> <p>A) Patient meets BOTH of the following (i and ii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Oncology – Braftovi Prior Authorization (PA) Policy</i> criteria; AND ii. Patient meets ONE of the following (a or b): <ul style="list-style-type: none"> a) Patient has tried Tafinlar; OR b) Patient is currently receiving Braftovi; OR <p>B) If the patient has met the standard <i>Oncology – Braftovi PA Policy</i> criteria, but has not met the exception criteria above (Aii), offer to review for the Preferred Product using the standard <i>Oncology – Tafinlar PA Policy</i> criteria.</p> <p>3. Other Conditions: Approve for 1 year if the patient meets the standard <i>Oncology – Braftovi PA Policy</i> criteria.</p>

Non-Preferred Product	Exception Criteria
Mektovi	<p>1. Melanoma, BRAF V600 Mutation-Positive Disease: Approve for 1 year if the patient meets ONE of the following (A <u>or</u> B):</p> <p>A) Patient meets BOTH of the following (i <u>and</u> ii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Oncology – Mektovi Prior Authorization (PA) Policy</i> criteria; AND ii. Patient meets ONE of the following (a <u>or</u> b): <ul style="list-style-type: none"> a) Patient has tried one of Cotellic or Mekinist; OR b) Patient is currently receiving Mektovi; OR <p>B) If the patient has met the standard <i>Oncology – Mektovi PA Policy</i> criteria, but has not met the exception criteria above (Aii), offer to review for one of the Preferred Products using either the standard <i>Oncology – Cotellic PA Policy</i> criteria <u>or</u> the <i>Oncology – Mekinist PA Policy</i> criteria.</p> <p>2. Non-Small Cell Lung Cancer, BRAF V600E Mutation-Positive Disease: Approve for 1 year if the patient meets ONE of the following (A <u>or</u> B):</p> <p>A) Patient meets BOTH of the following (i <u>and</u> ii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Oncology – Mektovi Prior Authorization (PA) Policy</i> criteria; AND ii. Patient meets ONE of the following (a <u>or</u> b): <ul style="list-style-type: none"> a) Patient has tried Mekinist; OR b) Patient is currently receiving Mektovi; OR <p>B) If the patient has met the standard <i>Oncology – Mektovi PA Policy</i> criteria, but has not met the exception criteria above (Aii), offer to review for the Preferred Product using the standard <i>Oncology – Mekinist PA Policy</i> criteria.</p> <p>3. Other Conditions: Approve for 1 year if the patient meets the standard <i>Oncology – Mektovi PA Policy</i> criteria.</p>

REFERENCES

1. Cotellic™ tablets [prescribing information]. South San Francisco, CA: Genentech/Roche; May 2023.
2. Mekinist® tablets [prescribing information]. East Hanover, NJ: Novartis; August 2023.
3. Tafinlar® capsules [prescribing information]. East Hanover, NJ: Novartis; August 2023.
4. Zelboraf® tablets [prescribing information]. South San Francisco, CA: Genentech; May 2020.
5. Mektovi® tablets [prescribing information]. Boulder, CO: Array BioPharma; October 2023.
6. Braftovi™ capsules [prescribing information]. Boulder, CO: Array BioPharma; October 2023.
7. The NCCN Melanoma Clinical Practice Guidelines in Oncology (version 2.2023 – March 10, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 6, 2023.
8. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 7.2024 – June 26, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on August 9, 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	Effective 01/01/2024	10/11/2023
Selected Revision	Policy Effective: 01/01/2024. For Braftovi and Mektovi exception criteria to be consistent, deleted the verbiage "...experienced inadequate efficacy, significant intolerance, or other exceptional clinical circumstance".	10/18/2023
Early Annual Revision	Non-Small Cell Lung Cancer, BRAF V600E Mutation-Positive Disease: Added Preferred and Non-Preferred Products for this indication. Also added new exception criteria for the Non-Preferred products.	08/21/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.